Wednesday, January 01, 2014 7:22:57 PM
This KOL is screaming Bavi in this article. Bavi WIPES out MDSCs. The KEY to everything.
Check the author's name....a KEY KOL!
Myeloid-derived Suppressor Cells as a Critical Element of Tumor Microenvironment
The Wistar Institute, 3601 Spruce St., Philadelphia, PA
Myeloid-derived Suppressor Cells as a Critical Element of Tumor Microenvironment:
Biological Role and Target for Therapeutic Intervention
Dmitry Gabrilovich, M.D., Ph.D.
H. Lee Moffitt Cancer Center & Research Institute
I agree sulaco... and nice to have Dmitri Gabrilovich as a top notch scientific advisor for Peregrine Pharmaceuticals, also looks like he'll have a conference in late June to attend.
---------------------------------------------------------------
The 4TH International Conference on Notch Targeting in Cancer
Date: June 25-27, 2014
Venue: Santa Marina Hotel, Mykonos, Greece
The fourth annual international conference devoted to Notch Biology and related Cancer Therapeutics will include basic and translational research, preclinical and clinical studies,
biomarker discovery and progress achieved thus far in this emerging and exciting field of targeting Notch, as examined and presented by leading scientists in the
field. Examples of speakers and preliminary topics include:
Dmitry Gabrilovich, The Wistar Institute, USA:
Effects of Notch Signaling on Regulation of Myeloid Cell
Differentiation in Cancer
http://www.cancerconferences.org/annual_meetings/PRELIMINARY-ANNOUNCEMENT-2014-conferences.pdf
---------------------------------------------------------------
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
